Strata Skin Sciences Inc Stock Price, News & Analysis

STRATA Skin Sciences (NASDAQ: SSKN), a medical technology company focused on dermatologic treatments, announces its participation in the D. Boral Capital Inaugural Global Conference on May 14, 2025. The event will take place at The Plaza Hotel in New York City, where CEO Dr. Dolev Rafaeli will conduct one-on-one meetings from 9:00 AM to 3:00 PM ET. Interested parties can register for meetings through John Perez at D. Boral Capital.

STRATA Skin Sciences (NASDAQ: SSKN), a medical technology company focused on dermatologic treatments, has scheduled its first quarter 2025 financial results announcement for May 14, 2025 after market close. The company will host a conference call at 5:00 p.m. ET the same day, featuring management remarks and a Q&A session.

Interested U.S. participants can join via phone at 1-866-524-3160 (domestic) or 1-412-317-6760 (international). A live webcast will also be available. The call replay will be accessible until May 21, 2025, through multiple channels including phone (1-877-344-7529 or 1-412-317-0088) with access code 6753445, and webcast replay available until September 21, 2025.

STRATA Skin Sciences (NASDAQ: SSKN) reported Q4 2024 financial results with revenue of $9.6 million, up 10% year-over-year. The company's global XTRAC® recurring revenue reached $5.5 million, while equipment revenue increased 23% to $3.8 million.

Full-year 2024 revenue was $33.6 million, slightly up from $33.4 million in 2023. Q4 gross margin improved to 60.1%, up 480 basis points from the previous year. The company reduced its domestic XTRAC® installed base to 864 devices while increasing average revenue per device to $5,906 (+6% YOY).

Notable developments include renewed 3-year agreements with distributors in China and Japan, XTRAC Momentum™ 1.0 device approval in Japan, and a $2.1 million registered direct offering. The company reported a net loss of $4.5 million for Q4 2024 and ended the year with $8.6 million in cash and equivalents.

STRATA Skin Sciences (NASDAQ: SSKN), a medical technology company focused on dermatologic treatments, has scheduled its Fourth Quarter and Year End 2024 financial results announcement for March 27, 2025 after market close.

The company will host a conference call at 4:30 p.m. ET on the same day, featuring management's remarks and a Q&A session. Investors can access the call through domestic (1-844-481-2523) or international (1-412-317-0552) dial-in numbers.

A webcast replay will be available until September 21, 2025, while telephonic replay access will be available until April 3, 2025 using the code 8210574.

STRATA Skin Sciences (NASDAQ: SSKN) announces results from a new Japanese study validating the superiority of narrow band Excimer Laser over Excimer Light for treating skin conditions. The study, published in the Journal of Nippon Medical School, demonstrates that despite both devices using 308-nm wavelength, the Excimer Laser's unique properties lead to better clinical outcomes.

Key findings show that XTRAC® Excimer Laser achieves:

• Deeper penetration into hair follicles
• Greater activation of melanocyte lineage cells
• Fewer epidermal side effects
• Faster treatment delivery (1 second vs 20 seconds for 1,000 mJ/cm²)

STRATA has expanded its presence in Japan with over 100 devices placed, including 24 in 2024. The company's global footprint includes over 1,800 devices in the United States and 1,000 internationally.

STRATA Skin Sciences (NASDAQ: SSKN), a medical technology company focused on dermatologic treatments, has announced its participation in the Benchmark Company 13th Annual Discovery Investor Conference. The event will take place on Wednesday, December 11, 2024, at the New York Athletic Club in New York City.

Dr. Dolev Rafaeli, President and Chief Executive Officer, will be available for one-on-one meetings with analysts and investors throughout the conference day. Interested attendees can arrange meetings through their Benchmark Company representative, and general conference registration is available online.

STRATA Skin Sciences (NASDAQ: SSKN) reported Q3 2024 revenue of $8.8 million, down 1% year-over-year. Global net recurring revenue increased 2% to $5.4 million. The company achieved its first non-GAAP operating profit of $128,000 since 2018, excluding a one-time $1.8 million tax accrual. Gross margin improved to 60.3% from 56.0% year-over-year. The domestic installed base reached 873 XTRAC® devices and 135 TheraClear®X devices. The company raised $2.1 million through a stock offering in July 2024. Net loss was $2.1 million or $0.53 per share, compared to a net loss of $1.1 million or $0.30 per share in Q3 2023.

STRATA Skin Sciences (NASDAQ: SSKN) announces a favorable court order in its complaint against LaserOptek, Monarch Laser Services, and The Pinnacle Health Group. The order, issued by the US District Court for Eastern Pennsylvania, enjoins LaserOptek and Pinnacle from marketing Pallas lasers with claims about CPT Codes 96920-96922 reimbursement and prohibits false statements about Pallas or STRATA lasers. The ruling follows STRATA's August 2024 complaint citing unfair competition. The company will continue pursuing claims for equitable and monetary relief, defending against what it describes as misleading practices regarding non-excimer laser reimbursement claims.